mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.
Boehringer Ingelheim has bought Nerio Therapeutics, saying that it is adding a programme that – while still in preclinical development – could be a "centrepiece" of its immuno-oncology pipe
Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patient
Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern.
Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappo
AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.